Molecure S.A. (WSE:MOC)
5.30
-0.10 (-1.85%)
Nov 4, 2026, 5:03 PM CET
Molecure Earnings Call Transcripts
Fiscal Year 2024
-
Two main clinical programs advanced, with QATD-01 (sarcoidosis) and QATD-02 (solid tumors) progressing in enrollment and dose escalation, respectively. Financials show reduced costs and stable capital, with ongoing efforts to secure partnerships and grants to fund future development.